Eli Lilly halts trial testing experimental muscle-preserving drug with Zepbound
Sept 25 (Reuters) – Eli Lilly (LLY.N), has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due to strategic business reasons, according to a U.S. registry of clinical trials. The company was testing the drug, bimagrumab, alone or in combination with Lilly’s tirzepatide, the active ingredient in its […]
Eli Lilly halts trial testing experimental muscle-preserving drug with Zepbound Read More »









